<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36308536</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1619-7089</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur J Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>Role of brain 2-[<sup>18</sup>F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>784</StartPage><EndPage>791</EndPage><MedlinePgn>784-791</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-022-05987-3</ELocationID><Abstract><AbstractText Label="PURPOSE">The identification of prognostic tools in amyotrophic lateral sclerosis (ALS) would improve the design of clinical trials, the management of patients, and life planning. We aimed to evaluate the accuracy of brain 2-[<sup>18</sup>F]fluoro-2-deoxy-D-glucose-positron-emission tomography (2-[<sup>18</sup>F]FDG-PET) as an independent predictor of survival in ALS.</AbstractText><AbstractText Label="METHODS">A prospective cohort study enrolled 418 ALS patients, who underwent brain 2-[<sup>18</sup>F]FDG-PET at diagnosis and whose survival time was available. We discretized the survival time in a finite number of classes in a data-driven fashion by employing a k-means-like strategy. We identified "hot brain regions" with maximal power in discriminating survival classes, by evaluating the Laplacian scores in a class-aware fashion. We retained the top-m features for each class to train the classification systems (i.e., a support vector machine, SVM), using 10% of the ALS cohort as test set.</AbstractText><AbstractText Label="RESULTS">Data were discretized in three survival profiles: 0-2 years, 2-5 years, and &gt; 5 years. SVM resulted in an error rate &lt; 20% for two out of three classes separately. As for class one, the discriminant clusters included left caudate body and anterior cingulate cortex. The most discriminant regions were bilateral cerebellar pyramid in class two, and right cerebellar dentate nucleus, and left cerebellar nodule in class three.</AbstractText><AbstractText Label="CONCLUSION">Brain 2-[<sup>18</sup>F]FDG-PET along with artificial intelligence was able to predict with high accuracy the survival time range in our ALS cohort. Healthcare professionals can benefit from this prognostic tool for planning patients' management and follow-up. 2-[<sup>18</sup>F]FDG-PET represents a promising biomarker for individual patients' stratification in clinical trials. The lack of a multicentre external validation of the model warrants further studies to evaluate its generalization capability.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5876-4079</Identifier><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Martino</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Business and Management, LUISS University, Viale Romania 32, 00197, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palumbo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabras</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Pede</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arena</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Positron Emission Tomography Centre AFFIDEA-IRMET S.p.A., Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giuliani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Environment and Health Department, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute of Turin (NIT), Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute of Turin (NIT), Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pagani</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="N">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2-[18F]FDG-PET</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Prediction model</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList><CoiStatement>Prof Calvo has received a research grant from Cytokinetics. Prof Chi&#xf2; serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Biogen, Cytokinetics, Denali Therapeutics, Amylyx, and AveXis. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36308536</ArticleId><ArticleId IdType="pmc">PMC9852209</ArticleId><ArticleId IdType="doi">10.1007/s00259-022-05987-3</ArticleId><ArticleId IdType="pii">10.1007/s00259-022-05987-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet Lond Engl. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler Off Publ World Fed Neurol Res Group Mot Neuron Dis. 2009;10:310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen C, Caga J, Mahoney CJ, Kiernan MC, Huynh W. Behavioural changes predict poorer survival in amyotrophic lateral sclerosis. Brain Cogn. 2021;150:105710. doi: 10.1016/j.bandc.2021.105710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bandc.2021.105710</ArticleId><ArticleId IdType="pubmed">33725515</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, He B, Zhang Y, Chen L, Fan D, Zhan S, et al. Prognostic models for amyotrophic lateral sclerosis: a systematic review. J Neurol. 2021;268(9):3361&#x2013;3370. doi: 10.1007/s00415-021-10508-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10508-7</ArticleId><ArticleId IdType="pubmed">33694050</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K, Vanhee A, Verschueren J, De Coster L, Driesen A, Dupont P, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71:553&#x2013;561. doi: 10.1001/jamaneurol.2014.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.62</ArticleId><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Ceccarini J, Delva A, Robberecht W, Van Damme P, Van Laere K. Prospective validation of 18F-FDG brain PET discriminant analysis methods in the diagnosis of amyotrophic lateral sclerosis. J Nucl Med Off Publ Soc Nucl Med. 2016;57:1238&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">26940764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanovello M, Sorar&#xf9; G, Campi C, Anglani M, Spimpolo A, Berti S, et al. Brain stem glucose hypermetabolism in amyotrophic lateral sclerosis/frontotemporal dementia and shortened survival: an 18F-FDG PET/MRI study. J Nucl Med Off Publ Soc Nucl Med. 2022;63:777&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">34503963</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burgh HK, Schmidt R, Westeneng H-J, de Reus MA, van den Berg LH, van den Heuvel MP. Deep learning predictions of survival based on MRI in amyotrophic lateral sclerosis. NeuroImage Clin. 2017;13:361&#x2013;369. doi: 10.1016/j.nicl.2016.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.10.008</ArticleId><ArticleId IdType="pmc">PMC5219634</ArticleId><ArticleId IdType="pubmed">28070484</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Spinelli EG, Riva N, Fontana A, Basaia S, Canu E, et al. Survival prediction models in motor neuron disease. Eur J Neurol. 2019;26:1143&#x2013;1152. doi: 10.1111/ene.13957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13957</ArticleId><ArticleId IdType="pubmed">30920076</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS functional rating scale. Amyotroph Lateral Scler Front Degener. 2014;15:279&#x2013;284. doi: 10.3109/21678421.2014.897357.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.897357</ArticleId><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, N&#xe5;gren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103&#x2013;2110. doi: 10.1007/s00259-009-1264-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-009-1264-0</ArticleId><ArticleId IdType="pubmed">19838705</ArticleId></ArticleIdList></Reference><Reference><Citation>Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12:575&#x2013;593. doi: 10.1007/s12021-014-9235-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12021-014-9235-4</ArticleId><ArticleId IdType="pubmed">24952892</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho SY, Wong L, Goh WWB. Avoid oversimplifications in machine learning: going beyond the class-prediction accuracy. Patterns N Y N. 2020;1:100025. doi: 10.1016/j.patter.2020.100025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.patter.2020.100025</ArticleId><ArticleId IdType="pmc">PMC7660406</ArticleId><ArticleId IdType="pubmed">33205097</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Cai D, Niyogi P. Laplacian score for feature selection. In: proceedings of the 18th international conference on neural information processing systems. NIPS&#x2019;05. Vancouver, British Columbia, Canada: MIT Press, 2005, pp. 507&#x2013;514.</Citation></Reference><Reference><Citation>Vapnik VN. Statistical learning theory. New York: Wiley; 1998.</Citation></Reference><Reference><Citation>Snoek J, Larochelle H, Adams RP. Practical Bayesian optimization of machine learning algorithms. Proc 25th Int Conf Neural Inf Process Syst -, vol. 2. Red Hook, NY, USA: Curran Associates Inc.; 2012. p. 2951&#x2013;9.</Citation></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594. doi: 10.1136/bmj.g7594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g7594</ArticleId><ArticleId IdType="pubmed">25569120</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Melazzini MG, Maestri E, Sansone VA. Amyotrophic lateral sclerosis survival score (ALS-SS): a simple scoring system for early prediction of patient survival. Amyotroph Lateral Scler Front Degener. 2015;17:93&#x2013;100. doi: 10.3109/21678421.2015.1083585.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1083585</ArticleId><ArticleId IdType="pubmed">26470943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020;167:107986. doi: 10.1016/j.neuropharm.2020.107986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.107986</ArticleId><ArticleId IdType="pubmed">32062193</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Kliest T, van den Berg LH. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. Curr Opin Neurol. 2020;33:655&#x2013;661. doi: 10.1097/WCO.0000000000000861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000861</ArticleId><ArticleId IdType="pubmed">32796282</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, et al. Revised Airlie house consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610&#x2013;e1623. doi: 10.1212/WNL.0000000000007242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Anterior cingulate cortex TDP-43 pathology in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2018;77:74&#x2013;83. doi: 10.1093/jnen/nlx104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx104</ArticleId><ArticleId IdType="pubmed">29186496</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M, Chio A, Valentini MC, Oberg J, Nobili F, Calvo A, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitoma H, Buffo A, Gelfo F, Guell X, Fuc&#xe0; E, Kakei S, et al. Consensus paper. Cerebellar reserve: from cerebellar physiology to cerebellar disorders. Cerebellum Lond Engl. 2020;19:131&#x2013;153. doi: 10.1007/s12311-019-01091-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12311-019-01091-9</ArticleId><ArticleId IdType="pmc">PMC6978437</ArticleId><ArticleId IdType="pubmed">31879843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ib&#xe1;&#xf1;ez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer&#x2019;s disease. Neurology. 1998;50:1585&#x2013;1593. doi: 10.1212/WNL.50.6.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.50.6.1585</ArticleId><ArticleId IdType="pubmed">9633698</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutillo CM, Sharma KR, Foschini L, Kundu S, Mackintosh M, Mandl KD, et al. Machine intelligence in healthcare-perspectives on trustworthiness, explainability, usability, and transparency. NPJ Digit Med. 2020;3:47. doi: 10.1038/s41746-020-0254-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-0254-2</ArticleId><ArticleId IdType="pmc">PMC7099019</ArticleId><ArticleId IdType="pubmed">32258429</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>